Oragenics Announces Strategic Partnership With Receptor.AI To Accelerate Pipeline Development (Oragenics)
UF Innovate | Accelerate graduate Oragenics announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio for potential conditions affecting brain health.
Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial
UF Innovate | Accelerate graduate Oragenics, Inc., announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development
UF Innovate | Accelerate graduate Oragenics, Inc., has announced a manufacturing agreement with Sterling Pharma Solutions, a leading U.S.-based CDMO with multiple development and production facilities.
Oragenics, Inc. Announces Approval To Initiate Phase II Concussion Drug Trial in Australia
UF Innovate | Accelerate graduate Oragenics announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase II clinical trial evaluating ONP-002 for the treatment of mild traumatic brain injury (mTBI).
Oragenics, Inc. To Participate at the 15th Annual Traumatic Brain Injury Conference
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company developing novel intranasal therapies for concussion and other brain-related conditions, announced its participation in the 15th Annual Traumatic Brain Injury Conference.
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
UF Innovate | Accelerate graduate Oragenics announced that it has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee (HDEC) in New Zealand.
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury
UF Innovate | Accelerate graduate Oragenics, Inc. announced the submission of its Investigator’s Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia.
Oragenics, Inc. Announces Partnership With BRAINBox Solutions To Revolutionize Concussion Diagnosis and Treatment
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI).
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
UF Innovate | Accelerate graduate Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity.
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics, Inc., a UF Innovate | Accelerate alumnus company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.